跳至主要内容
临床试验/JPRN-UMIN000014638
JPRN-UMIN000014638已完成未知

Investigation of the efficacy and safety of ipragliflozin in obese patients with type 2 diabetes undergoing metformin (Met) - Investigation of the efficacy and safety of ipragliflozin in obese patients with type 2 diabetes undergoing metformin (Met)

Association of medical corporation Toyukai, Yutenji Medical Clinic0 个研究点目标入组 35 人开始时间: 2014年7月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Type 1 diabetes 2) Has history of hypersensitivity to ipragliflozin or any other excipient of ipragliflozin 3) With severe ketosis, diabetic coma, or precoma 4) With severe infection, pre or post surgery, and serious trauma 5) Has history of lactic acidosis 6) With severe hepatic disorder 7) With gastrointestinal disorder such as diarrhea or vomiting, concerning dehydration or dehydration status 8) Moderate or severe renal dysfunction (Serum Creatinine male: >= 1.3 mg/dL, female: >= 1.2 mg/dL) 9) Has stroke, myocardial infarction, or other serious cardiovascular complications requiring hospitalization within 6 months 10) Is receiving SGLT-2 inhibitor, insulin therapy at initiation 11) Is pregnant, nursing, or planned to become pregnant 12) Considered as inadequate by the investigator

研究者

发起方
Association of medical corporation Toyukai, Yutenji Medical Clinic

相似试验

Investigation of the efficacy and safety of... | 临床试验